T he first reported use of salicylate-rich plants as an analgesic and anti-inflammatory agent comes from the Ebers Papyrus, an Egyptian medical text from ca. 1,543 bc. 1 It wasn't until the mid-1800s that silicon was isolated as the active component from willow tree bark extract, and then purified to acetylsalicylic acid. Bayer patented the compound in 1900, after the German chemist Felix Hoffmann's successful use of it to treat his father's severe arthritis. Finally, in 1950, the physician Lawrence Craven recognized that aspirin reduced the risk of heart attacks in men. 2 The cardioprotective benefits of aspirin are probably a result of its ability to inhibit the formation of prostaglandins and thromboxane A 2 (potent promoters of platelet aggregation and vasoconstriction, through the irreversible inhibition of the COX-1 enzyme). Although the prevention of thrombosis is desirable in certain patient populations, such an effect also increases the risk of serious bleeding complications, including intracranial hemorrhage. In patients without verified vascular disease, the determination of benefits and risks has proved difficult.
Texas Heart Institute Journal
Aspirin for Cardiovascular Disease Prevention 319 patients taking aspirin for both primary and secondary prevention trials. The conclusion was that, despite the similarity of relative-risk reduction in primary and secondary prevention, the absolute number of events (and therefore the absolute risk reduction) was dramatically lower in primary prevention. This relationship held true in all subgroup analyses. Furthermore, the benefit is almost entirely in reduction of MI, without a major effect on vascular mortality rates.
Given the idiosyncrasies of these data sets, organizational guidelines tend to differ in their recommendations for aspirin use in primary prevention. The ACC/ AHA primary-prevention guidelines for aspirin include a level A, class I recommendation for the use of low-dose aspirin in men and a level B, class IIa recommendation for women-all of whom have an estimated cardiovascular risk score of >10% over the next 10 years. 6 The United States Preventive Services Task Force provides a practical approach. In order to assist the physician and the patient in deciding whether to start aspirin for primary prevention, it tabulates the risk-benefit analysis for MI reduction in men of age 45 to 79 years by using risk of MI versus risk of GI bleeding and intracranial hemorrhage, and it tabulates the risk-benefit analysis for stroke reduction in women of age 55 to 79 years by using risk of GI bleeding alone. 7 Currently, there are several ongoing studies (for example, the ARRIVE, 8 ASPREE, 9 ASCEND, 10 and ACCEPT-D 11 trials) of aspirin use for primary prevention in various subgroups, and of aspirin use in patients who are currently undergoing optimal medical therapy for the prevention of vascular disease.
